China Pharma Holdings, Inc.

CPHI

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001106644

E

weakest fifth of 369 graded peers in healthcare

rank 343 of 369; percentile 92.9; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	D percentile 73.2
Solvency	D percentile 73.4
Growth and financing	D percentile 69.2
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $31.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, late filer not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Apr 1, 2026 214 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.62 2026-10-30; market equity $26.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 1, 2026

(the "Company", "China Pharma", "we", "us", or "our") is a Nevada holding company. China Pharma is not a Chinese operating company and all the operations are conducted by our wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson") and Helpson's subsidiaries in China. We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China (the "PRC"). All of the operations are conducted in the PRC, where the manufacturing facilities are located.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 73.2						
Gross profitability	(0.4%)	32.4%		97.8	366	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31					
Accruals ratio	(14.5%)	(6.6%)	30.8	803	2025-12-31
Gross margin stability, five years	16.9 pts	2.8 pts	90.9	242	2025-12-31
Solvency, sleeve percentile 73.4					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(3.85)	(0.35)	50.6	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	0.32x	2.92x	96.3	829	2025-12-31
Growth and financing, sleeve percentile 69.2					
Revenue growth, three-year compound	(20.0%)	10.1%	89.5	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 14					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	20.3%	2.2%	21.2	696	2025-12-31
Net share issuance, one year	1,142.3%	2.5%	96.8	631	2026-03-25

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 1142.3%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
338	Precision Biosciences Inc. (DTIL)	91.6	E	dilution, fortress balance sheet
339	Beyond Air, Inc. (XAIR)	91.8	E	dilution, short runway, distress
340	Airsculpt Technologies, Inc. (AIRS)	92.1	E	late filer
341	Elutia Inc. (ELUT)	92.4	E	short runway, fortress balance sheet
342	Sutro Biopharma, Inc. (STRO)	92.7	E	dilution, short runway, distress, fortress balance sheet
343	China Pharma Holdings, Inc. (CPHI)	92.9	E	dilution, late filer
344	Celularity Inc. (CELU)	93.2	E	short runway, late filer
345	Fortress Biotech, Inc. (FBIO)	93.6	E	fortress balance sheet
346	Fortress Biotech, Inc. (FBIOP)	93.6	E	fortress balance sheet
347	Co-Diagnostics, Inc. (CODX)	94.0	E	dilution, short runway, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

348	Flyte Aviation, Inc. (VJET)	94.3	E	dilution, short runway, late filer, distress

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(59.9%)	(2.2%)	11
Distance from 52-week high	(92.3%)	(28.7%)	4
EBIT to enterprise value	(10.5%)	(1.4%)	33
Free cash flow yield	0.3%	(1.0%)	56
Book value to price	1.35	0.28	91
Sales to price	0.15	0.30	35
Composite equity issuance, five years	615.7%	20.5%	97
Relative strength against the sector, log excess return	(1.08)	(0.19)	11

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$304,874
Operating cash flow, four quarters	-$140,490
Months of runway	26.0
Days since last periodic filing	79 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$131,007

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	-$131,950	2025-12-31	2026-04-01	10-K	26-038521
2	assets	us-gaap:Assets	$31.0M	2025-12-31	2026-04-01	10-K	26-038521
3	operating income	us-gaap:OperatingIncomeLoss	-$10.4M	2018-12-31	2020-03-30	10-K	20-008020
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$10.9M	2018-12-31	2020-03-30	10-K	20-008020
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$109,989	2018-12-31	2020-03-30	10-K	20-008020
6	total debt	us-gaap:LongTermDebt	$6.5M	2018-12-31	2019-03-28	10-K	19-005094
7	book equity	us-gaap:StockholdersEquity	$30.2M	2018-12-31	2021-03-26	10-K	21-017981
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.2M	2018-12-31	2020-03-30	10-K	20-008020
9	total debt	us-gaap:LongTermDebt	$9.2M	2017-12-31	2018-04-02	10-K	18-003895
10	book equity	us-gaap:StockholdersEquity	$43.1M	2017-12-31	2020-03-30	10-K	20-008020
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2.0M	2017-12-31	2019-03-28	10-K	19-005094
12	net income	us-gaap:NetIncomeLoss	-$3.2M	2025-12-31	2026-04-01	10-K	26-038521
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$148,261	2025-12-31	2026-04-01	10-K	26-038521
14	assets	us-gaap:Assets	$14.9M	2024-12-31	2026-04-01	10-K	26-038521
15	revenue	us-gaap:Revenues	$4.1M	2025-12-31	2026-04-01	10-K	26-038521

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

16	gross profit	us-gaap:GrossProfit	-$2.0M	2024-12-31	2026-04-01	10-K	26-038521
17	revenue	us-gaap:Revenues	$4.5M	2024-12-31	2026-04-01	10-K	26-038521
18	gross profit	us-gaap:GrossProfit	-$281,085	2023-12-31	2025-03-31	10-K	25-026280
19	revenue	us-gaap:Revenues	$7.0M	2023-12-31	2025-03-31	10-K	25-026280
20	gross profit	us-gaap:GrossProfit	-$493,916	2022-12-31	2024-04-01	10-K	24-028731
21	revenue	us-gaap:Revenues	$8.1M	2022-12-31	2024-04-01	10-K	24-028731
22	gross profit	us-gaap:GrossProfit	$349,270	2021-12-31	2023-03-30	10-K	23-024710
23	revenue	us-gaap:Revenues	$9.6M	2021-12-31	2023-03-30	10-K	23-024710
24	current assets	us-gaap:AssetsCurrent	$2.3M	2025-12-31	2026-04-01	10-K	26-038521
25	current liabilities	us-gaap:LiabilitiesCurrent	$7.4M	2025-12-31	2026-04-01	10-K	26-038521
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$47.2M	2025-12-31	2026-04-01	10-K	26-038521
27	operating income	us-gaap:OperatingIncomeLoss	-$3.2M	2025-12-31	2026-04-01	10-K	26-038521
28	book equity	us-gaap:StockholdersEquity	$22.7M	2025-12-31	2026-04-01	10-K	26-038521
29	liabilities	us-gaap:Liabilities	$8.3M	2025-12-31	2026-04-01	10-K	26-038521
30	total debt	us-gaap:LongTermDebt	$5.2M	2020-12-31	2021-03-26	10-K	21-017981
31	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$957,653	2020-12-31	2022-03-30	10-K	22-016151
32	operating income	us-gaap:OperatingIncomeLoss	-$2.6M	2020-12-31	2022-03-30	10-K	22-016151
33	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$2.7M	2020-12-31	2022-03-30	10-K	22-016151
34	interest expense	us-gaap:InterestExpense	$27,272	2025-12-31	2026-04-01	10-K	26-038521
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$51,145	2018-12-31	2020-03-30	10-K	20-008020
36	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.3M	2018-12-31	2020-03-30	10-K	20-008020
37	current assets	us-gaap:AssetsCurrent	$8.7M	2018-12-31	2020-03-30	10-K	20-008020
38	current liabilities	us-gaap:LiabilitiesCurrent	$10.1M	2018-12-31	2020-03-30	10-K	20-008020
39	current assets	us-gaap:AssetsCurrent	$12.3M	2017-12-31	2019-03-28	10-K	19-005094
40	current liabilities	us-gaap:LiabilitiesCurrent	$9.2M	2017-12-31	2019-03-28	10-K	19-005094
41	assets	us-gaap:Assets	$16.5M	2023-12-31	2025-03-31	10-K	25-026280
42	assets	us-gaap:Assets	$17.8M	2022-12-31	2024-04-01	10-K	24-028731
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,522,002	2026-03-25	2026-04-01	10-K	26-038521
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,619,109	2025-03-24	2025-03-31	10-K	25-026280

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.